摘要:
The present invention provides a triheterocyclic peptide having first, second, and third 5-member heterocyclic moieties having the following formula CR.sub.3 CONH--Q.sup.1 --CONH--Q.sup.2 --CONH--Q.sup.3 -CONH--(CR.sub.3).sub.S --B, wherein Q.sup.1 is selected from a group consisting of: ##STR1## wherein Q.sup.2 is selected from a group consisting of: ##STR2## wherein Q.sup.3 is selected from a group consisting of: ##STR3## wherein at least one of A and Z is other than C; wherein A is C, N, O, or S; wherein B is N(CR.sub.3).sub.n or C(NH.sub.2).sub.2 ; wherein n is an integer from 2 to 10; wherein P is H, a lower alkyl or a halogen; wherein Q1, Q2, and Q3 are the same or different; wherein R is H, a lower alkyl group; wherein S is an integer from 1 to 10; wherein X' represents CR.sub.3, (CR.sub.2).sub.n --NRY, or (CR.sub.2).sub.n --CR.sub.2 Y; wherein X" represents CR.sub.3, (CR.sub.2).sub.n --NRY, or (CR.sub.2).sub.n --CR.sub.2 Y; wherein X'" represents CR.sub.3, (CR.sub.2).sub.n --NRY, or (CR.sub.2).sub.n --CR.sub.2 Y; wherein Y is a polyamine group, and wherein Z is C or N; wherein at least one of X', X", or X'" is other than CR.sub.3.
摘要:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
摘要:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
摘要:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.